RAPS flags the human element gap in AI device regulation as rules race to keep up
RAPS’ question about whether AI device regulations miss the human element gets at a central tension in health AI oversight: technical controls are advancing faster than frameworks for clinician judgment, workflow adaptation, and patient understanding. The issue is becoming more urgent as AI tools move from low-stakes support into more consequential clinical settings.
The most important part of the RAPS discussion is not the specific regulatory critique, but the framing: AI device oversight can become overly product-centric in a care environment where outcomes depend heavily on human behavior. An algorithm may be validated on paper, yet still underperform if clinicians misunderstand it, overtrust it, ignore it, or use it in workflows that differ from testing conditions.
That gap matters because many current AI governance tools are built around datasets, performance metrics, and update controls. Those are necessary, but they do not fully capture how humans absorb and act on machine outputs. The more regulators and manufacturers focus on the model, the easier it is to underweight training, interface design, explanation, escalation pathways, and the social dynamics of clinical decision-making.
This concern is also economically important. Health systems buying AI are discovering that implementation failure often has less to do with model quality than with local workflow fit and accountability design. If regulation does not encourage manufacturers to address those issues explicitly, buyers will have to absorb that burden themselves, slowing adoption and increasing variability.
In that sense, the ‘human element’ is not a soft add-on to AI regulation. It is where safety, effectiveness, and trust meet. The next generation of policy will likely need to treat human factors as central evidence, not auxiliary context, especially for tools that influence diagnosis, triage, or treatment decisions.